PARTNER 3 — 7-year follow-up: what it means for low-risk patients

Philippe Généreux and Philippe Pibarot discuss the long-term findings from PARTNER 3 and their practical implications for patient care.

They review the 7-year comparison of transfemoral TAVR versus surgical aortic-valve replacement in symptomatic patients with severe aortic stenosis who are at low surgical risk, and why the two strategies now show comparable rates for the composite endpoint of death, stroke and rehospitalisation.

The conversation examines valve performance and durability over time, pinpoints remaining challenges for both transcatheter and surgical approaches, and considers how these data should influence clinical decision-making. The speakers also reflect on the evolving role of the Heart Team when both options perform well long term and patient-centred choices become paramount.

This interview was filmed at PCR London Valves 2025: see more videos here.